TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

Overview of attention for article published in British Journal of Cancer, April 2009

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

patent: 5 patents

Readers on

mendeley: 68 Mendeley

So far, Altmetric has seen 5 patents that reference this research output.

Method of treating a cancer patient without the need for a tissue biopsy

Grant US-12195807-B2

United States of America

14 Jan 2025

METHOD OF TREATING A CANCER PATIENT WITHOUT THE NEED FOR A TISSUE BIOPSY

Application US-20220364186-A1

United States of America

17 Nov 2022

AFFINITY MATURED C-MET ANTIBODIES

Application EP-3909984-A1

European Patent Office

17 Nov 2021

BI-SPECIFIC ANTIBODIES FOR ENHANCED TUMOR SELECTIVITY AND INHIBITION AND USES THEREOF

Application WO-2017076492-A1

World Intellectual Property Organisation (WIPO)

11 May 2017

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 1 additional patents.